10.02.2021 • News

Clariant Finances Catalyst Research at ETH Zurich

Clariant has signed a cooperation agreement with the Swiss Federal Institute of Technology (ETH Zurich) to support research in catalysis and sustainable chemistry. It is providing the university with what it says is “a significant financial contribution” over an initial period of ten years. Terms were not disclosed.

The Swiss specialty chemicals group said the goal of the partnership is to advance the understanding of catalyst properties from nano- to macroscale as well as their performance. Together with the ETH Foundation, it will sponsor and collaborate in fundamental chemical research projects, promoting talented scientists and students.

Hans Bohnen, member of Clariant’s executive committee, said the partnership with ETH, like those with other academic institutions, underscores the chemicals group’s commitment to fostering innovation and R&D. Its latest cooperation expands its partnerships with prominent global academic institutions, including the Technical University of Munich, Germany, and top tier universities in China.

Detlef Guenther, vice president for research at ETH Zurich, said the collaboration with Clariant opens great opportunities for the university’s scientists and students to expand their knowledge in catalysis and benefit from first-hand expertise in the industrial application of novel technologies.

One of the world’s leading universities, the Zurich prestige school is currently recognized as the sixth best by QS World University Rankings. Since its founding in 1855, it has had a strong tradition in science and technology and has produced 21 Nobel Prize winners, including Albert Einstein.

Author: Dede Williams, Freelance Journalist

Clariant has signed an agreement with the Swiss Federal Institute of Technology...
Clariant has signed an agreement with the Swiss Federal Institute of Technology (ETH Zurich) to support research in catalysis and sustainable chemistry. It is providing the university with what it says is “a significant financial contribution” over a period of ten years. (c) Clariant

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.